March 2021 Br J Cardiol 2021;28:7–10 doi:10.5837/bjc.2021.007
Sarah Maria Birkhoelzer, Elena Cowan, Kaushik Guha
Introduction SARS-CoV-2 has rapidly become a worldwide health emergency. The declaration by the World Health Organisation (WHO) in March 2020 of a global pandemic has underscored the widespread morbidity and mortality caused by the virus. Concerted efforts by healthcare and research communities are ongoing to establish the efficacy and potency of various pharmacotherapeutics. It has been shown that coronavirus disease 2019 (COVID-19) affects multiple organs and has heterogeneous effects on the cardiovascular system. This is also accompanied by enhanced morbidity and mortality in patients with pre-existing cardiovascular disease.1 In urgent e
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits